A Phase IB/III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib Versus Placebo and Ruxolitinib in Patients With Intermediate- or High-Risk Myelofibrosis
Phase of Trial: Phase I/II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Vismodegib (Primary) ; Ruxolitinib
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors Roche
- 15 Mar 2018 Status changed to completed.
- 12 Dec 2017 Results assessing efficacy and safety of combined ruxolitinib and vismodegib, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 23 Nov 2017 Status changed from recruiting to discontinued.